Fortrea Holdings Inc. Common Stock (FTRE) — Analysis Summary
Fortrea Holdings Inc. Common Stock (FTRE) has a market cap of $2.00B with year-over-year revenue growth of +1.0%. Net margin stands at -36.2%. The stock trades at a P/E ratio of -23.4.
Key Takeaways
- Revenue changed +1.0% year-over-year
- Net margin of -36.2%
- P/E ratio of -23.4
Compared to other companies in the SERVICES-MEDICAL LABORATORIES sector, FTRE posted revenue growth of +1.0% and trades at a P/E of -23.4.
Fortrea Holdings Inc. Common Stock (FTRE)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Debt/EBITDA at 15.6x — highly leveraged, potential refinancing risk
Current ratio at 0.96x — current liabilities exceed current assets
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
Sector
SERVICES-MEDICAL LABORATORIES
Employees
14,000
Headquarters
DURHAM, NC
Exchange
XNAS
Systematic competitive advantage assessment based on 3yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.